

Type 2 diabetes in adults: management (medicines update) Guideline update – committee meeting 11

Date: Wednesday 3rd November 2021

Location: Virtual committee meeting by Zoom

Minutes: Final

Committee members present:		
Chizo Agwu	Chair	Present for notes 1 – 9
Sarah Ali	Consultant Diabetologist	Present for notes 1 – 5
Chirag Bakhai	GP	Present for notes 1 – 9
Neel Basudev	GP	Present for notes 1 – 9
Augustin Brooks	Consultant Diabetologist	Present for notes 1 – 9
Tembi Chinaire	Diabetes Nurse	Present for notes 1 – 9
Anne Dornhorst	Consultant Diabetologist	Present for notes 1 – 9
Dorothy Frizelle	Mental health professional	Present for notes 2 – 9
Hugh Gallagher	Renal Physician	Present for notes 2 – 9
Natasha Jacques	Pharmacist	Present for notes 1 – 9
Sallianne Kavanagh	Pharmacist	Present for notes 1 – 9
Sharon McCarthy	Diabetes Nurse	Present for notes 1 – 9
Soon Song	Consultant Diabetologist	Present for notes 1 – 9
Annette Swinkels	Lay member	Present for notes 1 – 9
Gosia Wamil	Cardiologist	Present for notes part of item 2, 3 – 9

NICE team in attendance:		
Sarah Catchpole	Senior Medical Editor	Present for notes 1 – 9
Jacqueline Durkin	Administrator	Present for note 1 only
Rupert Franklin	Guideline Commissioning Manager	Present for notes part of 3, 4 – 9
Chris Harris	Project Manager	Present for notes 1 – 9
Marie Harrisingh (MH)	Senior Technical Analyst	Present for notes 1 – 9
Johanna Hulme (<i>observing</i>)	Associate Director - Medicines Advice	Present for notes 6,7-8

Andrew Hutchinson	Technical Adviser - Medicines Education	Present for notes 8 only
Kusal Lokuge	Technical Analyst (Health Economics)	Present for notes 1 – 9
Caroline Mulvihill	Guideline Update Team Associate Director	Present for notes 1 – 4
Adam O’Keefe	Project Manager	Present for notes 1 – 2, part of 3
Joshua Pink	Technical Adviser (Health Economics)	Present for notes 2, 4 - 5
Eric Power (<i>observing</i>)	Programme Director - Medicines and Technologies Programme	Present for notes 1 – 6, part of 7
Philip Williams	Business Analyst	Present for notes 1 – 9
Sarah Wood	Medicines Adviser	Present for notes 1 – 9

Apologies:	
Corrinne Wykes	Lay member
Gregory Moran	Technical Analyst (NICE)

1. Welcome, declarations of interest and minutes review				
<p>The Chair welcomed the Committee members and attendees to the eleventh committee meeting on Type 2 diabetes in adults (medicines update).</p> <p>The Chair informed the Committee that apologies had been received, noted above.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, these are noted below. The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>				
Name	Job title, organisation	Declarations of Interest,	Type of interest	Decision taken
Sallianne Kavanagh	Committee member, Pharmacist	Working with CPPE to create educational materials for pharmacist about the management of Type 2 diabetes. Non-promotional. Small remuneration for time.	Direct financial	Declare and participate
Sallianne Kavanagh	Committee member, Pharmacist	Speaker at FIP diabetes webinar. Designing a competency	Direct, non-financial professional and personal	Declare and participate

		framework for diabetes related roles: learning from the United Kingdom. Non promotional.		
--	--	------------------------------------------------------------------------------------------	--	--

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

2. Stakeholder consultation comments relating to SGLT2s

The Chair introduced NICE Senior Technical Analyst, Marie Harrisingh, who took the committee through a discussion on the stakeholder comments received and asked specific questions related to the guideline content.

The Chair thanked MH for their presentation and the Committee for their feedback.

3. Stakeholder consultation comments relating to GLP-1s

Following a short break, the NICE technical team led by Senior Technical Analyst, Marie Harrisingh and the Committee continued to review stakeholder comments and consider these in relation to the draft guideline.

The Chair thanked all for their input.

4. Stakeholder consultation comments relating to CV risk assessment and terminology;

The Chair Marie Harrisingh and the Committee continued to review stakeholder comments in relation to cardiovascular risk assessment. The Chair thanked the Committee and the NICE team for their contributions.

5. Miscellaneous stakeholder consultation comments

The Committee continued to review and discuss the remaining stakeholder comments. The Chair thanked everyone for their feedback.

6 & 7. Visual summary discussions

The Chair introduced NICE Medicines Adviser, Sarah Wood, who took the Committee through an update and discussion on the visual summary and related stakeholder comments.

The Chair thanked SW for their presentation and the Committee for their contributions to the discussion.

8. Patient Decision Aid discussion

The Chair introduced NICE Technical Adviser, Andrew Hutchinson, who took the Committee through an update and discussion on the patient decision aid and related stakeholder comments.

The Chair thanked AH for their presentation and the Committee for their contributions to the

discussion.

9. AOB, next steps and summary

The Chair introduced Chris Harris who provided the committee with an overview of the next steps and deadlines in the run up to publication of this topic.

The Chair thanked the Committee for their contribution, summarised the main actions from the day and asked if there was any other business. As there was no further business, the Chair brought the meeting to a close.